Statements (62)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:acquisition |
acquired by Aytu Bio Pharma
|
| gptkbp:business_model |
focus on specialty pharmaceuticals
|
| gptkbp:ceo |
Yasmin A. K. Khoshbin
|
| gptkbp:clinical_trial |
conducts clinical trials for drug development
engages in clinical research collects clinical data for product efficacy conducts Phase III clinical trials participates in multi-center clinical trials |
| gptkbp:collaboration |
works with healthcare providers
|
| gptkbp:community_engagement |
engages with the community
|
| gptkbp:drug_safety |
ensures drug safety and efficacy
|
| gptkbp:employees |
approximately 100
|
| gptkbp:financial_performance |
reports financial performance quarterly
|
| gptkbp:financial_support |
offers patient support programs
|
| gptkbp:focuses_on |
central nervous system disorders
|
| gptkbp:founded |
gptkb:2011
|
| gptkbp:founder |
Yasmin A. K. Khoshbin
|
| gptkbp:funding |
receives funding for research initiatives
|
| gptkbp:has_advisory_board |
has a scientific advisory board
|
| gptkbp:head_of_state |
focuses on business development opportunities
|
| gptkbp:headquarters |
gptkb:Dallas,_Texas
|
| https://www.w3.org/2000/01/rdf-schema#label |
Neos Therapeutics
|
| gptkbp:instruction_set |
has a product pipeline for ADHD treatments
|
| gptkbp:invention |
holds patents for drug formulations
|
| gptkbp:investment |
maintains investor relations department
receives venture capital funding publicly traded investors |
| gptkbp:market |
conducts market research for product development
|
| gptkbp:market_cap |
market capitalization varies
|
| gptkbp:market_launch |
launched Adzenys XR-ODT in 2016
launched Cotempla XR-ODT in 2018 |
| gptkbp:marketing_strategy |
focuses on niche markets
develops marketing strategies for products |
| gptkbp:mission |
improve patient outcomes
|
| gptkbp:partnership |
collaborates with academic institutions
partnership with various healthcare organizations |
| gptkbp:partnerships |
establishes partnerships with other companies
|
| gptkbp:patient_education |
provides patient education resources
|
| gptkbp:product |
Adzenys ER
Adzenys XR-ODT Cotempla XR-ODT focuses on innovative drug delivery systems |
| gptkbp:provides_guidance_on |
follows clinical guidelines for ADHD treatment
|
| gptkbp:regulatory_body |
gptkb:FDA
|
| gptkbp:regulatory_compliance |
FDA approved products
ensures regulatory compliance for products |
| gptkbp:research_areas |
psychiatry
|
| gptkbp:research_focus |
ADHD and related disorders
ADHD treatments |
| gptkbp:side_effect |
aims to have a positive impact on healthcare
|
| gptkbp:social_responsibility |
engages in corporate social responsibility initiatives
|
| gptkbp:stock_symbol |
NEOS
|
| gptkbp:supply_chain |
manages supply chain for pharmaceuticals
|
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:treatment |
aims to improve clinical outcomes
|
| gptkbp:type |
gptkb:public_company
|
| gptkbp:vision |
transform treatment for ADHD
|
| gptkbp:website |
www.neostherapeutics.com
|
| gptkbp:bfsParent |
gptkb:Aptensio_XR
gptkb:Quillivant_XR |
| gptkbp:bfsLayer |
6
|